CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Study of the PARP Inhibitor Talazoparib in Advanced Cancer Patients With Somatic Alterations in BRCA1/2, Mutations/Deletions in Other BRCA Pathway Genes and Germline Mutation in BRCA1/2 (Not Breast or Ovarian Cancer)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02286687
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:43.414283+00:00
Published At: 2026-01-02T00:00:00+00:00
Record Updated At: 2026-01-02
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Advanced Malignant Neoplasm", "ATM Gene Mutation", "BRCA1 Gene Mutation", "BRCA2 Gene Mutation", "Metastatic Malignant Neoplasm", "PALB2 Gene Mutation", "Recurrent Malignant Neoplasm", "Refractory Malignant Neoplasm"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-01-02"
protocolSection.identificationModule.nctId: "NCT02286687"
protocolSection.identificationModule.officialTitle: "Phase II Study of the PARP Inhibitor Talazoparib in Advanced Cancer Patients With Somatic Alterations in BRCA1/2, Mutations/Deletions in Other BRCA Pathway Genes and Germline Mutation in BRCA1/2 (Not Breast or Ovarian Cancer)"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.